Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: Pharmacol Ther. 2023 Oct 21;251:108545. doi: 10.1016/j.pharmthera.2023.108545

Figure 5. Mechanisms of NLRP3 activation in tumor.

Figure 5.

(Top) Tumor cell-intrinsic mechanisms of NLRP3 activation in the TME. (Bottom) Host cell-intrinsic mechanisms of NLRP3 activation in the TME. Aberrant activation of NLRP3 within the TME results in increased IL-1β and IL-18 secretion. Dysregulation of these cytokines result tumor promoting mechanisms, such as; angiogenesis, immunosuppression and metastasis. NLRP3 activation therefore represents a key immune checkpoint within the TME, acting as a master switch for inflammation-mediated tumor progression.